What it's for (Indications)
- Amlodipine + hydrochlorothiazide + valsartan is indicated for the treatment of essential hypertension.
- This triple combination therapy is typically prescribed for patients whose blood pressure is not adequately controlled with monotherapy or dual therapy containing any of the individual components.
- It aims to provide comprehensive blood pressure reduction through multiple complementary mechanisms, making it suitable for managing moderate to severe hypertension and reducing the risk of cardiovascular events such as stroke and myocardial infarction.
- The specific formulation and dosage are determined by individual patient needs, clinical response, and the presence of any comorbidities that might influence treatment choice.
- This medication offers a multi-faceted approach to blood pressure management, targeting different physiological pathways involved in hypertension.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of amlodipine + hydrochlorothiazide + valsartan should be individualized based on the patient's prior antihypertensive therapy, clinical response, and tolerability, always striving for the lowest effective dose. This combination is available in various strengths (e.g., varying amounts of amlodipine, hydrochlorothiazide, and valsartan), allowing for flexible titration and tailored treatment. It is typically administered orally once daily, with or without food. Patients should be adequately hydrated and any pre-existing electrolyte abnormalities (especially hypokalemia) corrected prior to initiating therapy with the diuretic component. Careful and regular monitoring of blood pressure, renal function (e.g., serum creatinine, eGFR), and serum electrolytes (e.g., potassium, sodium) is essential during dosage adjustment and throughout the entire course of treatment to ensure optimal therapeutic benefit, minimize adverse effects, and detect any potential complications. The maximum recommended daily dose for each individual component should not be exceeded when using the combination product. |
Safety & Warnings
Common Side Effects
- Common side effects associated with amlodipine + hydrochlorothiazide + valsartan often include dizziness, headache, nasopharyngitis, and peripheral edema, particularly attributable to the amlodipine component.
- Other frequently reported adverse reactions may involve fatigue, orthostatic hypotension (a drop in blood pressure upon standing), and various electrolyte disturbances such as hypokalemia, hyponatremia, and hypochloremic alkalosis, along with hyperuricemia and hyperglycemia, which are commonly associated with the hydrochlorothiazide component.
- Gastrointestinal issues like nausea, abdominal pain, diarrhea, or constipation, as well as musculoskeletal pain (e.
- g.
- , back pain, arthralgia), cough, and urinary tract infections, have also been observed.
- Patients may experience palpitation or flushing due to the vasodilatory effects of amlodipine.
- While generally well-tolerated, it is crucial for patients to report any new or worsening symptoms to their healthcare provider for evaluation and appropriate management.
- Serious but less common side effects can include severe hypotension, renal dysfunction, angioedema, and allergic reactions.
- This list is not exhaustive, and individual patient responses to the medication can vary significantly.
- Regular follow-up with a healthcare professional is strongly recommended to monitor for and effectively manage potential adverse drug reactions.
Serious Warnings
- Black Box Warning: **WARNING: FETAL TOXICITY** **When pregnancy is detected, discontinue amlodipine + hydrochlorothiazide + valsartan as soon as possible.** Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. There have been several dozen cases reported in the world literature in patients who were taking angiotensin converting enzyme inhibitors. When pregnancy is detected, discontinue amlodipine + hydrochlorothiazide + valsartan as soon as possible. The use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue amlodipine + hydrochlorothiazide + valsartan as soon as possible. These adverse outcomes are usually associated with the use of these drugs in the second and third trimesters of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate treatment of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus. In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue amlodipine + hydrochlorothiazide + valsartan, unless it is considered life-saving for the mother. Fetal testing may be appropriate, depending on the week of pregnancy. Patients and physicians should be aware that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to amlodipine + hydrochlorothiazide + valsartan for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as a means of reversing hypotension and/or substituting for impaired renal function.
- **Serious Warnings:** Patients receiving amlodipine + hydrochlorothiazide + valsartan should be closely monitored for several potential serious adverse effects.
- **Hypotension:** Symptomatic hypotension, particularly in volume-depleted patients (e.
- g.
- , those on high-dose diuretics or with severe congestive heart failure), or those undergoing dialysis, can occur.
- Volume or salt depletion should be corrected prior to initiating therapy.
- **Renal Impairment:** Dual blockade of the Renin-Angiotensin-Aldosterone System (RAAS) with angiotensin receptor blockers (ARBs), ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
- Most patients should not receive concomitant aliskiren and ARB therapy.
- Renal function should be monitored periodically, especially in patients with pre-existing renal impairment, renovascular hypertension, or those with severe congestive heart failure.
- **Hyperkalemia:** May occur, particularly in patients with renal impairment, diabetes mellitus, or those concurrently taking potassium-sparing diuretics, potassium supplements, or other drugs that increase serum potassium levels.
- **Hepatic Impairment:** Exercise caution in patients with mild to moderate hepatic impairment; the drug is contraindicated in severe hepatic impairment, biliary cirrhosis, or cholestasis.
- **Electrolyte Imbalance:** Hydrochlorothiazide can cause hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia.
- Hypercalcemia may also occur.
- Serum electrolytes should be monitored regularly.
- **Acute Myopia and Secondary Angle-Closure Glaucoma:** Hydrochlorothiazide can cause an idiosyncratic reaction resulting in acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks of drug initiation.
- Symptoms include acute onset of decreased visual acuity or ocular pain.
- This requires immediate discontinuation of the drug.
- **Lupus Erythematosus:** Thiazide diuretics may exacerbate or activate systemic lupus erythematosus.
- **Aortic/Mitral Stenosis or Obstructive Hypertrophic Cardiomyopathy:** As with all vasodilators, special caution is advised in patients with severe aortic stenosis, severe mitral stenosis, or obstructive hypertrophic cardiomyopathy due to the risk of reduced cardiac output and hypotension.
- **Increased Angina or Myocardial Infarction:** Rarely, patients, particularly those with severe obstructive coronary artery disease, have developed documented increased frequency, duration, or severity of angina or acute myocardial infarction on initiation of calcium channel blocker therapy or at the time of dosage increase.
How it Works (Mechanism of Action)
Amlodipine + hydrochlorothiazide + valsartan combines three distinct antihypertensive agents with complementary mechanisms of action to provide comprehensive and potent blood pressure control. **Amlodipine**, a dihydropyridine calcium channel blocker, acts by inhibiting the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. This action leads to a reduction in peripheral vascular resistance and peripheral arterial vasodilation, thereby lowering systemic blood pressure. **Hydrochlorothiazide** (HCTZ) is a thiazide diuretic that exerts its primary effect in the cortical diluting segment of the renal tubule, where it inhibits the reabsorption of sodium and chloride ions. This pharmacological action results in an increased excretion of sodium, chloride, and water, leading to a reduction in circulating plasma volume and direct arteriolar dilation, both contributing significantly to its antihypertensive effect. **Valsartan**, an angiotensin II receptor blocker (ARB), specifically and selectively blocks the binding of angiotensin II to the AT1 receptor, which is found in various tissues, including vascular smooth muscle, the adrenal gland, and the kidney. Angiotensin II is a potent endogenous vasoconstrictor and plays a crucial role in stimulating aldosterone secretion. By blocking the effects of angiotensin II at the AT1 receptor, valsartan induces vasodilation, reduces aldosterone secretion, and decreases renal sodium reabsorption, collectively resulting in a substantial reduction in blood pressure. Unlike ACE inhibitors, ARBs do not inhibit the breakdown of bradykinin, which may contribute to a lower incidence of cough. The synergistic action of these three agents addresses multiple, distinct pathways involved in blood pressure regulation, leading to a more potent, sustained, and multifaceted antihypertensive effect.
Commercial Brands (Alternatives)
No other brands found for this formula.